Comprehensive Profiling of Hypoxia-Related miRNAs Identifies miR-23a-3p Overexpression as a Marker of Platinum Resistance and Poor Prognosis in High-Grade Serous Ovarian Cancer

Paola Todeschini 1,2,4, Elisa Salviato 3,†,‡, Chiara Romani 1,*, Vittoria Raimondi 4,†, Francesco Ciccarese 4,†, Federico Ferrari 2,5, Germana Tognon 2, Sergio Marchini 6, Maurizio D’Incalci 6, Laura Zanotti 1,2, Antonella Ravaggi 1,2,5,‡, Franco Odicino 2,5, Enrico Sartori 2,5, Donna M. D’Agostino 4,7,*, Michele Samaja 8,†, Chiara Romualdi 3,‡ and Eliana Bignotti 1,2,*,†

Abstract: The onset of chemo-resistant recurrence represents the principal cause of high-grade serous ovarian carcinoma (HGSOC) death. HGSOC masses are characterized by a hypoxic microenvironment, which contributes to the development of this chemo-resistant phenotype. Hypoxia regulated-miRNAs (HRMs) represent a molecular response of cancer cells to hypoxia and are involved in tumor progression. We investigated the expression of HRMs using miRNA expression data from a total of 273 advanced-stage HGSOC samples. The miRNAs associated with chemoresistance and survival were validated by RT-qPCR and target prediction, and comparative pathway analysis proposed that the miR23a-3p/PAF1 axis could be considered a possible target for personalized medicine in HGSOC patients.

Simple Summary: In the present paper, we identified miR-23a-3p, a hypoxia regulated-microRNA (miRNA), as a potential biomarker of chemoresistance and poor outcome in two independent cohorts of high-grade serous ovarian carcinoma (HGSOC) patients. Then, we predicted the involvement of miR-23a-3p in the platinum resistance pathway, together with its target APAF-1 gene, and validated their anticorrelation and association with platinum response in HGSOC patients and cell lines. We propose that the evaluation of miR-23a-3p expression may provide important clinical indications on patients not responding to platinum treatment and that the miR23a-3p/PAF1 axis could be considered a possible target for personalized medicine in HGSOC patients.

Citation: Todeschini, P.; Salviato, E.; Romani, C.; Raimondi, V.; Ciccarese, F.; Ferrari, F.; Tognon, G.; Marchini, S.; D’Incalci, M.; Zanotti, L.; et al. Comprehensive Profiling of Hypoxia-Related miRNAs Identifies miR-23a-3p Overexpression as a Marker of Platinum Resistance and Poor Prognosis in High-Grade Serous Ovarian Cancer. Cancers 2021, 13, 3358. https://doi.org/10.3390/cancers13133358

Academic Editor: Ruud L. M. Bekkers

Received: 15 April 2021
Accepted: 25 June 2021
Published: 4 July 2021

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
downregulated in platinum-resistant patients and in HGSOC chemo-resistant cells. These results highlight miR-23a-3p as a potential biomarker for HGSOC platinum response and prognosis and the miR23a-3p/APAF1 axis as a possible target to overcome platinum-resistance.

**Keywords:** miRNA; hypoxia; ovarian cancer; platinum response; prognostic marker; miR-23a-3p; APAF1

1. **Introduction**

Ovarian carcinoma (OC) represents the fifth leading cause of cancer death among women worldwide [1], with high-grade serous ovarian carcinoma (HGSOC) the most common and aggressive histological type. HGSOC develops rapidly and is frequently diagnosed at an advanced stage when multiple synchronous tumor lesions are localized to the ovary, as well as in other anatomical sites within the peritoneal cavity [2]. Resistance to chemotherapy is one of the major challenges in HGSOC clinical management since, after a positive initial response to primary treatment, most patients develop platinum-resistant recurrence, a lethal disease for which effective therapies do not exist [2]. The rapid expansion of HGSOC tumor masses requires the presence of a vascular network supplying oxygen and nutrients essential for their growth. However, when tumor cell proliferation exceeds angiogenesis, the highly abnormal microvasculature fails to cover the oxygen requirement, and tumor cells are exposed to an O2-deficient environment [3]. This persistent hypoxic condition induces changes in HGSOC gene expression that promote cancer progression, invasion as well as resistance to chemotherapy and the “angiogenic switch”, through transcriptional activation of the pro-angiogenic vascular endothelial growth factor (VEGF) gene [4,5]. Consequently, angiogenesis is considered an attractive target for ovarian cancer therapy with the anti-VEGF antibody Bevacizumab approved in the first-line setting, in addition to platinum and taxane combination, for patients with advanced-stage OC [6,7], as well as second-line treatment in combination with platinum and gemcitabine [8]. However, no molecular biomarkers predictive of response to Bevacizumab currently exist, and patients are still selected for the drug only on the basis of their clinical characteristics (including stage, debulking status and presence of ascites). Over the past few years, protein-coding hypoxia-regulated genes have been joined by specific miRNAs, thus adding a new paradigm of gene expression regulation to an already complex process and providing an additional link between tumor-specific stress conditions and gene expression control. The first evidence for a hypoxic cancer-related miRNA signature was described by Kulshreshtha et al., who reported a group of “hypoxia-regulated miRNAs” (HRMs), dysregulated in response to low oxygen tension in breast and colon cancer cell lines and involved in cancer cell survival in a stressful microenvironment [9]. In the present study (Figure 1), we investigated the role of HRMs in platinum response and prognosis in HGSOC patients by analyzing the expression of a panel of selected HRMs in a large collection of TCGA samples [10] and in samples from patients treated at ASST Spedali Civili di Brescia (Brescia, Italy). We identified and validated miR-23a-3p over-expression as associated with platinum resistance and worse prognosis. Pathway analyses, complemented by computationally predicted miRNA-gene interactions, identified a set of target genes involved in chemotherapy response and in particular APAF-1 gene, whose functional interactions with miR-23a-3p are likely to have an important role in HGSOC cell survival.
2. Materials and Methods

2.1. Selection of Candidate Hypoxia-Related miRNAs

Ovarian cancer-specific miRNAs related to hypoxia were selected from the literature following a Medline search using the MeSH terms ‘ovarian cancer’/’ovarian carcinoma’ and ‘microRNA’/’miRNA’ and ‘hypoxia’ [11–18] and from the study of Kulshreshtha et al. [9].

2.2. Patient Sample Cohorts

A total of 323 HGSOC tumor samples were gathered from two independent tumor tissue collections: 145 from the Brescia cohort and 178 catalogued in TCGA (Table 1 and Supplementary Methods, Section S1). Based on the time interval between the end of first-line chemotherapy and relapse (platinum-free interval, PFI), patients from the two cohorts were classified into three groups: (i) platinum-sensitive (Pt-s, PFI > 12 months), (ii) platinum-partially sensitive (Pt-ps, PFI within 6–12 months from the last round of chemotherapy), and (iii) platinum-resistant (Pt-r, PFI< 6 months) [19]. TCGA patients for whom PFI information was not available (due to incomplete or missing annotations) were excluded from the analysis. The study on the Brescia cohort was performed following the Declaration of Helsinki set of principles and approved by the Research Review Board—the
Ethics Committee—of the ASST-Spedali Civili, Brescia, Italy (study reference number: NP1676). Written informed consent was obtained from all patients enrolled.

Table 1. Clinicopathological characteristics of HGSOC patients in the Brescia and TCGA cohorts.

| Clinical Annotations                  | Brescia Cohort | TCGA Cohort |
|--------------------------------------|----------------|-------------|
| Total No. of patients                | 145            | 178         |
| Age                                  |                |             |
| Median (range) years                 | 62 (36–85)     | 60 (35–88)  |
| Histotype                            |                |             |
| Serous                               | 145 (100%)     | 178 (100%)  |
| FIGO Classification                  |                |             |
| III                                  | 112 (77%)      | 159 (89%)   |
| IV                                   | 33 (23%)       | 19 (11%)    |
| Residual Tumor (RT)                  |                |             |
| RT = 0                               | 41 (28%)       | 44 (25%)    |
| RT > 0                               | 104 (72%)      | 134 (75%)   |
| Treatment                            |                |             |
| Carboplatin + Paclitaxel             |                |             |
| Sensitive                            | 48 (33%)       | 60 (34%)    |
| Partially Sensitive                  | 23 (16%)       | 41 (23%)    |
| Resistant                            | 48 (33%)       | 68 (38%)    |
| NA                                   | 4 (3%)         | -           |
| Carboplatin + Paclitaxel + Bevacizumab| 22 (15%)      | 9 (5%)      |
| Platinum Status                      |                |             |
| Carboplatin + Paclitaxel             |                |             |
| Sensitive                            | 7 (5%)         | 1 (0.5%)    |
| Partially Sensitive                  | 6 (4%)         | 1 (0.5%)    |
| Resistant                            | 9 (6%)         | 7 (4%)      |
| Median follow-up, years (range)      | 3.6 (0–15)     | 2.62 (0–12.7)|
| Median PFS, months (range)           | 23.7 (1.7–172.6)| 15.3 (0.8–111.7)|
| Median OS, months (range)            | 43.7 (1.2–177.3)| 33.3 (0.8–152.9)|

2.3. Tissue Sample Collection and RNA Extraction

Tissue sample collection and RNA extraction were performed as previously described [20] and detailed in Supplementary Methods, Section S2.

2.4. miRNA and Gene Expression Profiles

Gene and miRNA microarray experiments were carried out on 95 HGSOC tissue samples from the Brescia cohort, as previously described [20,21] and detailed in Supplementary Methods, Section S3.

2.5. Validation by RT-qPCR

The miRNA validation using RT-qPCR was performed on 145 HGSOC tissue samples from the Brescia cohort, as previously described [22] and detailed in Supplementary Methods, Section S4.

2.6. miRNA Normalization Strategy

To accurately quantify miRNA levels, a reliable normalization relative to an endogenous miRNA is mandatory [23]. To identify stable miRNAs acting as normalizers for RT-qPCR expression data, we combined data from the literature with those resulting as invariant in our cohort of HGSOC microarray data, as detailed in Supplementary Methods, Section S5.
2.7. Cell Line Transfection and Apoptotic Cell Death Detection

All the materials and methods regarding silencing and overexpressing miR-23a-3p in HGSOC cell line models are reported in Supplementary Methods, Section S8–S13.

2.8. Statistical Analysis

All statistical analyses were performed using the R software (R Foundation for Statistical Computing, Vienna, Austria; version 3.4.0).

2.8.1. Pre-Processing and Differential Expression Analysis

The miRNA counts (TCGA, see Supplementary Methods, Section S1) were used to test for differential expression in RNA-seq experiments by use of the negative binomial distribution (DEseq2 package, version 1.18.1) [24]. Quantile normalization (limma package, version 3.34.9) [25], after log-transformation (base 2) of pseudo-counts, was used for survival analysis. Log-transformed (base 2) microarray data (Brescia cohort, see Supplementary Methods, Section S1)—for both miRNA and mRNA expression profiles—were normalized using the loess method, and the empirical Bayes test (limma package, version 3.34.9) [25] was performed for the differential expression analysis.

The miRNA expression profiles of cells with stemlike characteristics (OV A-BS4 spheroids), derived from a primary human HGSOC cell line as previously described [26] and detailed in Supplementary Methods Sections S6 and S7, were normalized with quantile normalization, after log-transformation of probes intensities. Normalized matched mRNA profiles were downloaded from ArrayExpress (E-MTAB-4799) [26].

2.8.2. RT-qPCR Data and Equivalence Analysis

RT-qPCR data from different groups were compared using a t-test for raw Cq and delta-normalized values (two- and one-tail, respectively). Equivalence of reference candidates between Pt-s and Pt-r patients was assessed using the two one-sided test (TOST) approach (equivalence package, version 0.7.2) [27], with the adoption of the default confidence level (alpha = 0.05). To ensure adequate power of the test, the equivalence range (±$\varepsilon$) was chosen depending on data variability following Wellek criteria [28].

2.8.3. Survival Analysis

The associations between miRNA profiles and survival outcomes were assessed with the Cox proportional hazard (CoxPH) model (survival R package, version 2.43–3), both in univariate and multivariate analysis. Patients were stratified into groups based on quartiles of the normalized ($-\Delta$Cq) expression level distribution. Overall Survival (OS) was defined as the time from the date of diagnosis to the day of death or last follow-up. Progression Free Survival (PFS) was defined as the time from the date of diagnosis to the date of the first recurrence/progression or last follow-up.

2.8.4. Over-Representation Analysis

The microT-CDS (version 5.0) [29] and TargetScan (release 7.2) [30] web servers were used to identify predicted interactions between miRNA-23a-3p and target genes. Only miRNA-mRNA interactions with miTG scores greater than 0.7 and context++ scores less than 0 (default parameters) were selected (1506 and 1342, respectively). In order to assess whether a certain biological pathway was significantly enriched for a certain miRNA, we performed an over-representation analysis (ORA) based on the hypergeometric test, as proposed by Backes et al. [31]. KEGG pathway annotations were retrieved using graphite R package (version 1.28.2) [32]. The $p$-values were computed using as background the number of validated targets (225) over the total number of annotated genes (5620) for the entire collection of considered pathways (303). Bonferroni corrections were applied to account for multiple testing. Information on experimentally supported miRNA targets was retrieved from DIANA-TarBase v8 [33].
3. Results

3.1. Patient Cohort Description

The clinicopathologic characteristics of 145 HGSOC patients belonging to the Brescia cohort and 178 patients from TCGA cohort are summarized in Table 1. All of the patients in the Brescia cohort were diagnosed with high-grade serous histological type and staged according to FIGO guidelines as stage III (77%) or IV (23%). Patients were followed from the date of surgery until death or the latest record retrieved, August 2018 (median follow-up, 3.6 years; range, 0–15 years). The median age at diagnosis was 62, and the median overall survival (OS) time was 43.7 months (range 1.2–177.3 months). Similarly, all 178 TCGA patients were diagnosed with high-grade serous histological type and staged according to FIGO guidelines as stage III (89%) or IV (11%). Patients were followed from the date of surgery until death or the latest record retrieved (median follow-up, 2.62 years; range, 0–12.7 years). The median age at diagnosis was 60, and the median overall survival (OS) time was 33.3 months (range 0.8–152.9 months).

3.2. Selection of Hypoxia-Related miRNAs

A Medline search was performed to identify HRMs with a potential role in HGSOC, and eight articles were selected [11–18]. A total of 8 ovarian cancer-specific miRNAs related to hypoxia and selected from the abovementioned Medline search [11–18], together with 20 HRMs reported by Kulshreshtha et al. [9], were included in the study (see Supplementary Results, Table S1). Three miRNAs were in common between the 2 groups; hence, a total of 25 miRNAs were selected for further analysis.

3.3. Evaluation of HRMs in HGSOC Datasets

Expression levels of the 25 selected miRNAs were derived from microarray data of 95 HGSOC patients of the Brescia cohort [20] and from published RNA Seq data of 178 TCGA patients (TCGA/OV project, see Supplementary Methods), and correlated with response to treatment and prognosis. Three miRNAs (miR-106a-3p, miR-138 and miR-630) were discarded because they were undetected in RNA-seq data, thus yielding 22 miRNAs for further analysis. HGSOC patients were classified as ‘Pt-r’ or ‘Pt-s’ based on their response to carboplatin treatment in the Brescia and TCGA cohorts (73 and 136 samples, respectively; see Materials and Methods), and the expression of the 22 miRNAs was evaluated by comparing the 2 groups. Results showed that miR-181c-5p and miR-23a-3p were significantly over-expressed in platinum-resistant patients in both cohorts (adjusted \( p \)-value ≤ 0.05, Table 2). The prognostic significance of the two miRNAs was assessed by univariate and multivariate models, accounting for age and residual tumor. As shown in Table 3, both miRNAs were found to be associated with PFS in the Brescia cohort, by both univariate and multivariate analysis (\( p \)-value ≤ 0.05), while neither miRNA was significantly associated with OS (Supplementary Results, Table S2).

| miRNA Name         | Brescia Cohort—Microarray 73 Samples (39 Pt-r, 34 Pt-s) | TCGA Cohort—RNA-seq 136 Samples (75 Pt-r, 61 Pt-s) |
|--------------------|--------------------------------------------------------|--------------------------------------------------|
|                    | Log 2(FC) | AveExpr | Adj. \( p \)-Value | Log 2(FC) | Mean | Adj. \( p \)-Value |
| hsa-miR-103a-3p    | 0.125     | 9.956   | 0.358                | 0.174     | 44316 | 0.324               |
| hsa-miR-107        | 0.058     | 9.317   | 0.682                | 0.131     | 152.4 | 0.323               |
| hsa-miR-125b-5p    | 0.493     | 10.508  | 0.040 **             | −0.195    | 10786.2 | 0.327             |
| hsa-miR-145-5p     | 0.602     | 7.031   | 0.032 **             | −0.169    | 3572.4 | 0.314               |
| hsa-miR-181a-5p    | 0.403     | 7.724   | 0.034 **             | −0.019    | 11434.2 | 0.915              |
| hsa-miR-181b-5p    | 0.374     | 5.776   | 0.309                | 0.208     | 1374.8 | 0.228               |
| hsa-miR-181c-5p    | 0.547     | 4.896   | 0.036 **             | 0.650     | 223.2 | 0.004 ***           |
| hsa-miR-192-5p     | −0.082    | 4.712   | 0.740                | 0.241     | 223.4 | 0.230               |

**Table 2.** Differential expression analysis. Differential expression analysis for 22 miRNAs in platinum-resistant (Pt-r) compared to platinum-sensitive (Pt-s) patients.
Table 2. Cont.

| miRNA Name        | Brescia Cohort—Microarray 73 Samples (39 Pt-r, 34 Pt-s) | TCGA Cohort—RNA-seq 136 Samples (75 Pt-r, 61 Pt-s) |
|-------------------|--------------------------------------------------------|--------------------------------------------------------|
|                   | Log 2(FC) AveExpr Adj. p-Value Log 2(FC) Mean Adj. p-Value | |
| hsa-miR-195-5p    | 0.173 7.756 0.475 0.187 6.7 0.351 | |
| hsa-miR-199a-3p   | 0.684 9.412 0.027 ** 0.064 618.8 0.740 | |
| hsa-miR-199a-5p   | 0.856 7.886 0.012 ** 0.308 770.8 0.161 | |
| hsa-miR-21-5p     | 0.065 13.243 0.759 0.221 11189.6 0.268 | |
| hsa-miR-21-3p     | 0.091 7.215 0.703 0.182 2141.6 0.305 | |
| hsa-miR-210       | 0.023 8.001 0.910 0.035 1574.9 0.866 | |
| hsa-miR-23a-3p    | 0.363 10.310 0.007 *** 0.286 6830.0 0.033 ** | |
| hsa-miR-23b-3p    | 0.177 9.554 0.389 0.183 4070.9 0.266 | |
| hsa-miR-24-3p     | 0.008 10.460 0.945 0.252 3371.5 0.058 * | |
| hsa-miR-26a-5p    | 0.188 10.206 0.138 0.081 1902.6 0.572 | |
| hsa-miR-26b-5p    | 0.106 9.162 0.480 0.015 265.4 0.917 | |
| hsa-miR-27a-3p    | 0.440 10.151 0.002 *** 0.193 1397.1 0.208 | |
| hsa-miR-30b-5p    | 0.313 9.202 0.089 * 0.140 186.4 0.429 | |
| hsa-miR-93-5p     | 0.023 8.001 0.910 0.035 1574.9 0.866 | |

Adjusted p-value (FDR). * <0.1 ** <0.05 *** <0.01. Highlighted in bold: significant miRNAs (p value ≤ 0.05) in both cohorts.

Table 3. Progression-free survival analysis. Univariate and multivariate Progression-free survival (PFS) analysis (Coxph) for miR-23a-3p and miR-181c-5p expression in both cohorts.

| miRNA Name       | Univariate | Multivariate (1) |
|------------------|-------------|-----------------|
|                  | Hazard SE   | p-Value         |
|                  |             | Hazard SE       | p-Value |
| hsa-miR-23a-3p   | 1.819 0.250 | 0.017 **        | 2.003 0.257 | 0.007 *** |
| hsa-mir-181c-5p  | 1.349 0.111 | 0.007 **        | 1.268 0.113 | 0.037 ** |

Brescia Cohort—95 samples

| hsa-miR-23a-3p   | 1.072 0.112 | 0.539           | 1.076 0.113 | 0.517 |
| hsa-mir-181c-5p  | 1.026 0.070 | 0.715           | 1.036 0.072 | 0.627 |

TCGA Cohort—178 samples

(1) Multivariate model accounted for age and residual tumor (2 classes: RT = 0 and RT > 0). ** <0.05 *** <0.01. Highlighted in bold: significant miRNAs (p value ≤ 0.05).

3.4. Validation of miR-23a-3p and miR-181c-5p Expression by RT-qPCR

The miR-23a-3p and miR-181c-5p expression was assessed by RT-qPCR on 145 HGSOC tissues from the Brescia cohort (including the 95 samples already profiled for miRNA expression) and associated with platinum response and survival.

The miR-23a-3p was confirmed to be significantly up-regulated in Pt-r compared to Pt-s patients (p-value = 0.03, Table 4 and Figure 2A). Multivariate survival analysis, accounting for residual tumor age and Bevacizumab treatment response on the entire Brescia cohort, revealed miR-23a-3p over-expression as an independent predictor of worse OS and PFS (Table 5 and Supplementary Results, Table S3). As expected, a strong association of known prognostic factors, such as age and residual tumor, with both OS and PFS (p-value ≤ 0.01) was found (Supplementary Results, Table S3). Moreover, as reported in the literature [34,35], treatment with Bevacizumab was confirmed to have a beneficial effect only on PFS. Stratification of the patients based on miR-23a-3p expression yielded a clear separation of the PFS curves, with patients in the lowest quartile of expression showing significantly longer PFS than patients in the middle or highest expression quartiles (HR = 1.92, Supplementary Results, Table S4 and Figure 2B).
Table 4. Differential expression analysis. The miR-23a-3p and miR-181c-5p expression in Pt-r ($n = 48$) and Pt-s ($n = 48$) patients evaluated by RT-qPCR (Brescia cohort).

| miRNA Name       | Mean (sd) Cq | Mean (sd) $-\Delta$Cq (1) | Cq       | $-\Delta$Cq (1) |
|------------------|--------------|----------------------------|----------|-----------------|
|                  | Pt-r         | Pt-s                       |          | Stat (95%CI)    | p-Value  | Stat (95%CI) | p-Value  |
| hsa-miR-23a-3p   | 24.82 (1.3)  | 25.39 (1.3)  | -0.56 (1.0) | -1.04 (1.1) | -2.140 (Inf, -0.128) | 0.017 ** | 1.910 (0.063, Inf) | 0.030 ** |
| hsa-miR-181c-5p  | 30.61 (2.3)  | 31.09 (2.5)  | -6.35 (2.1) | -6.73 (2.6) | -0.965 (Inf, 0.345) | 0.169 | 0.812 (0.404, Inf) | 0.209 |

(1) reference miR-16-5p. ** $p < 0.05$. One-side, T-test analysis. Highlighted in bold: significant.

Figure 2. Prognostic performance of miR-23a-3p in the Brescia cohort. (A) Violin plots and error bars (mean +/− standard deviation) showing normalized miR-23a-3p expression levels measured by RT-qPCR in HGSOC samples from platinum-resistant patients (Pt-r) compared to platinum-sensitive patients (Pt-s) ($p$-value = 0.03, one-sided t-test). Complete results in Table 4. (B) Progression-free survival curves (Coxph model adjusted by residual tumor, age and Bevacizumab), stratified by quartiles of normalized miR-23a-3p expression levels (Q1: low; Q2−Q3: moderate; Q4: high). Complete results in Supplementary Results Table S4. (**) $p \leq 0.05$, (***) $p \leq 0.01$.

Notably, miR-23a-3p was prognostic for PFS even in the subgroup of 22 patients treated with Bevacizumab, when accounting for residual tumor and age (HR = 1.8, Supplementary Results, Table S5).

Due to its significant association with response to platinum and prognosis, we selected miR-23a-3p for further investigations.

3.5. miR-23a-3p Expression in Ovarian Carcinoma Stem-Like Cells

As cancer stem cells (CSCs) have the fundamental property of being resistant to both chemotherapy and radiation, we tested whether miR-23a-3p might be deregulated in these cells. Our group recently isolated a population of cells with stemlike characteristics (OVA-BS4 spheroids) from a primary HGSOC cell line and characterized their miRNA and mRNA expression profiles by microarrays ([26] and Supplementary Methods, Section S7).
Using these datasets, we evaluated the expression of miR-23a-3p in CSC cells compared to their parental lines (Figure 3A). In agreement with our hypothesis, we found miR-23a-3p resulted significantly up-regulated in the OVA-BS4 spheroid cell line compared to parental cells (p-value = 0.013, one-tail t-test).

Table 5. Overall and progression-free survival analysis. OS and PFS analysis (Coxph) for miR-23a-3p and miR-181c-5p expression evaluated by RT-qPCR in Brescia cohort samples (n = 145). Complete results for the multivariate analysis in Supplementary Results, Table S3.

| miRNA Name    | Univariate-A∆q (1) | Multivariate (2)-A∆q (1) |
|---------------|--------------------|-------------------------|
|               | Hazard (95% CI)    | SE         | p-Value | Hazard (95% CI) | SE     | p-Value |
| hsa-miR-23a-3p| 1.149 (0.977–1.352)| 0.083      | 0.092 * | 1.195 (1.027,1.390) | 0.077 | 0.021 ** |
| hsa-miR-181c-5p| 1.026 (0.940–1.121)| 0.045      | 0.561   | 1.025 (0.938,1.119) | 0.045 | 0.587 |

Overall Survival (OS)

Progression-Free Survival (PFS)

| miRNA Name    | Univariate-A∆q (1) | Multivariate (2)-A∆q (1) |
|---------------|--------------------|-------------------------|
| hsa-miR-23a-3p| 1.178 (1.016–1.366)| 0.075      | 0.030 ** | 1.244 (1.071,1.446) | 0.077 | 0.004 *** |
| hsa-miR-181c-5p| 1.034 (0.957–1.118)| 0.040      | 0.399   | 1.040 (0.960,1.127) | 0.041 | 0.346 |

(1) reference miR-16-5p; (2) Multivariate model accounted for residual tumor (2 classes: RT = 0 and RT > 0), age and Bevacizumab. * <0.10 ** <0.05 *** <0.01. Highlighted in bold: significant.

Figure 3. The miR-23a-3p in HGSOC-Stemlike cells. (A) Range (bars) and mean (points) for miR-23a-3p expression levels measured by microarray in stemlike cell replicates from OVA-BS4 spheroids (1) compared to the parental cell line replicates (2) (p-value = 0.013, one-tail t-test). (B) Anti-correlation between miR-23a-3p and APAF1 expression levels measured by matched miRNA/gene microarray (p-value = 0.061, Pearson’s product-moment). (*) p ≤ 0.1, (**) p ≤ 0.05.
3.6. In Silico miR-23a-3p Target Prediction and Comparative Pathway Analysis

We performed an in silico target analysis using two different algorithms (TargetScan and microT-CDS), resulting in a set of 753 common predicted targets (Jaccard index: 33.4%). We then performed ORA analysis comparing—for each pathway—the observed with the expected number of targets. Twenty out of 303 analyzed pathways (6.6%) were identified as significantly enriched (adjusted $p$-value $\leq 0.001$). Interestingly, the ‘platinum drug resistance’ pathway showed the second most prominent enrichment (Table 6), suggesting the involvement of miR-23a-3p in this process.

Table 6. Over-representation analysis of KEGG pathways for miR-23a-3p target genes. Differentially expressed pathways (Adjusted $p$-value $\leq 0.01$).

| Pathway                                | No. Genes | No. Targets | $-\log_{10}$ (adj. $p$-Value) | Target                                                                 |
|----------------------------------------|-----------|-------------|-------------------------------|------------------------------------------------------------------------|
| 1 Renal cell carcinoma                  | 56        | 13          | 15.32                         | ARNT; ARNT2; CREBBP; CRK; EGLN2; GAB1; MET; PIK3CB; PIK3R3; PAK3; PAK6; TGFA; RAP1A |
| 2 Platinum drug resistance             | 39        | 8           | 10                            | APAF1; BCL2; FAS; PDPK1; PIK3CB; PIK3R3; XIAP; MAP3K5                   |
| 3 Hedgehog signalling pathway          | 47        | 8           | 8.21                          | CSNK1G1; CSNK1G3; CUL3; HHIP; SMURF2; SPOPL; BCL2; GSK3B                |
| 4 EGFR tyrosine kinase inhibitor resistance | 79      | 11          | 7.41                          | BCL2; FGF2; GAB1; I66R; JAK1; MET; PIK3CB; PIK3R3; PTEN; TGFA; GSK3B   |
| 5 ErbB signalling pathway               | 85        | 11          | 6.59                          | CRK; ERBB4; GAB1; PAK3; PAK6; PIK3CB; PIK3R3; TGFA; GSK3B; CBLB; STAT5B |
| 6 Bacterial invasion of epithelial cells | 53      | 7           | 5.57                          | CRK; GAB1; MET; PIK3CB; PIK3R3; WASL; DN3M                               |
| 7 Non-small cell lung cancer            | 65        | 8           | 5.34                          | EML4; PDPK1; PIK3CB; PIK3R3; RXRG; TGFA; STAT5B; STK4                 |
| 8 Glycosphingolipid biosynthesis—lacto and neolacto series | 27 | 4 | 4.72 | FUT4; FUT9; GCNT2; ST8SIA1 |
| 9 p53 signalling pathway                | 71        | 8           | 4.61                          | APAF1; BCL2; CCNG1; FAS; PTEN; RCHY1; SESN2; SESN3                   |
| 10 mTOR signalling pathway              | 142       | 15          | 4.51                          | ATP6V1B2; ATP6V1C1; ATP6V1E1; FNIP2; FZD4; FZD5; GSK3B; LRP5; PDPK1; PIK3CB; PIK3R3; PTEN; SEH1L; SESN2; CHUK |
| 11 Prostate cancer                      | 85        | 9           | 4.25                          | CHUK; CREBBP; GSK3B; PDPK1; PIK3CB; PIK3R3; PTEN; TGFA; BCL2            |
| Pathway                                      | No. Genes | No. Targets | −log10 (adj. p-Value) | Target                                      |
|---------------------------------------------|-----------|-------------|-----------------------|---------------------------------------------|
| 12 Aldosterone-regulated sodium reabsorption | 30        | 4           | 4.2                   | NEDD4L; PDPK1; PIK3CB; PIK3R3               |
| 13 Measles                                   | 107       | 11          | 4.14                  | CBLB; CHUK; JAK1; PIK3CB; PIK3R3; RCHY1; TNFAIP3; GSK3B; FAS; IL12B; STAT5B |
| 14 Fc gamma R-mediated phagocytosis          | 91        | 9           | 3.66                  | ASAP1; CRK; PIK3CB; PIK3R3; PRKCE; WASL; CFL2; MARCKS; MARCKSL1 |
| 15 Adherens junction                         | 69        | 7           | 3.62                  | CSNK2A2; MET; TGFB2; WASL; YES1; TJP1; NLK  |
| 16 Small cell lung cancer                    | 92        | 9           | 3.57                  | APAF1; BCL2; CHUK; COL4A4; PIK3CB; PIK3R3; PTEN; RXRG; XIAP |
| 17 Mannose type O-glycan biosynthesis        | 23        | 3           | 3.49                  | CHST10; FUT4; FUT9                          |
| 18 Non-alcoholic fatty liver disease (NAFLD) | 71        | 7           | 3.42                  | FAS; IL6R; MAP3K5; PIK3CB; PIK3R3; GSK3B; CASP7 |
| 19 Phosphatidylinositol signalling system    | 86        | 8           | 3.1                   | DGKE; INPP5A; IPMK; PIK3C2A; PIK3CB; PIK3R3; PIP4K2B; PTEN |
| 20 IL-17 signalling pathway                  | 14        | 2           | 3.08                  | FOSB; TAB3                                  |

(1) Bonferroni correction.

To further investigate the link between miR-23a-3p and platinum drug resistance, we evaluated the expression correlation of miR-23a-3p with its eight predicted gene targets identified in the 'platinum drug resistance' pathway (Table 7). We explored miRNA-target correlation in two different datasets: (i) the matched HGSOC miRNA and gene expression profiles of the Brescia cohort [20,21], and (ii) the matched miRNA–mRNA dataset of microarray profiles of HGSOC-stemlike cells (OVA-BS4 spheroids) isolated from a primary HGSOC cell line [26] (Figure 3B). Assuming that increased miRNA expression induces target mRNA degradation and/or translational repression [36], we detected a consistent anticorrelation pattern (Pearson correlation) in both datasets only for the APAF1 gene (ρ = −0.227 and −0.79).

3.7. The miR-23a-3p/APAF1 Axis and Carboplatin Sensitivity

To functionally assess the miR-23a-3p-APAF1 interaction, we conducted a pilot in vitro study on an HGSOC primary cell line (OSPC2) and on the widely studied OC cell line OVCAR3, which express high and low miR-23a-3p levels, respectively (Figure S1). As described in the Supplementary Results, transfection of OSPC2 with a miR-23a-3p inhibitor resulted in an increase in APAF1 protein levels, while transfection of OVCAR3 cells with a miR-23a-3p mimic produced a reduction in APAF1 (Figures S2A,B and S3A,B). Further experiments provided evidence that miR-23a-3p suppresses apoptosis of tumor cells and confers platinum chemoresistance by regulating the expression of its direct target APAF1 (Figure S3C,D and Table S6).
Table 7. Predicted miR-23a-3p targets involved in platinum drug resistance pathway. Reported are TargetScan, microT-CDS scores and Pearson correlations between matched mRNAs and miRNA microarray expression profiles in the Brescia cohort (73 samples: 39 Pt-r, 34 Pt-s) and OVA-BS4 cell line (6 biological replicates: 3 spheroids vs. 3 parental).

| Symbol | Target Scan Context Score | microT−CDS miTGscore | Tarbase Experimentally Validated | Brescia Cohort Microarray Pearson Correlation | OVA−BS4 Cell Line Microarray Pearson Correlation |
|--------|---------------------------|----------------------|--------------------------------|---------------------------------------------|---------------------------------------------|
| APAF1  | −0.54                     | 0.96                 | Yes                            | −0.227                                      | −0.790                                      |
| BCL2   | −0.36                     | 0.73                 | No                             | 0.250                                       | 0.893                                       |
| FAS    | −0.51                     | 0.84                 | No                             | 0.124                                       | −0.783                                      |
| PDPK1  | −0.15                     | 0.92                 | Yes                            | −0.159                                      | −0.002                                      |
| PIK3CB | −0.17                     | 0.91                 | Yes                            | 0.040                                       | −0.201                                      |
| PIK3R3 | −0.17                     | 0.95                 | Yes                            | −0.126                                      | 0.927                                       |
| XIAP   | −0.28                     | 0.95                 | No                             | 0.052                                       | −0.907                                      |
| MAP3K5 | −0.08                     | 0.81                 | No                             | −0.038                                      | 0.816                                       |

Highlighted in bold: anti-correlated genes (< −0.1) in both considered datasets.

4. Discussion

Resistance to standard platinum-based chemotherapy is the principal cause of poor outcome in HGSOC patients [2]. Thus, the discovery of reliable biomarkers predictive of response is crucial to inform patient selection for effective and safe treatment strategies. In this study, starting from the hypothesis of the involvement of hypoxic miRNAs in a more aggressive HGSOC phenotype, we demonstrated that over-expression of miR-23a-3p correlates with chemo-resistant disease and is an independent biomarker of poor prognosis in HGSOC patients. Importantly, the role of this miRNA as a prognostic biomarker is independent from other well-recognized clinical characteristics, such as age and residual tumor. The association of miR-23a-3p expression with a more aggressive tumor phenotype has been previously reported in OC, both in tissues and in cell lines [37–43]. However, to our knowledge, this is the first study assessing miR-23a-3p expression by three different technologies in two independent cohorts of OC patients, clinically homogeneous regarding histotype (serous), tumor grade (high), stage (advanced) and treatment (first-line platinum-based chemotherapy). This result provides novel indications for the management of newly diagnosed HGSOC patients, by identifying women who may not benefit from platinum therapy and may be directed to alternative treatments. In addition, the evaluation of miR-23a-3p expression at relapse could help in identifying patients unlikely to respond to platinum who can be more efficiently treated with other regimens, avoiding the toxicity of unnecessary therapies. It is worth noting that miR-23a-3p over-expression retained its role as a marker of poor prognosis in the subgroup of patients treated with Bevacizumab, an anti-VEGF antibody that has been added to the OC standard of care first and second-line therapy regimens. The identification of biomarkers able to guide Bevacizumab treatment is still a pending issue, and our preliminary results indicate that miR-23a-3p might help to select OC patients who will benefit from antiangiogenic therapy. Consistent with our hypothesis of a role for miR-23a-3p in chemoresistance, we found that ‘platinum drug resistance pathway’ was one of the most enriched KEGG pathways for its mRNA targets. Evaluating the relationship of miR-23a-3p with the target mRNAs annotated in this pathway and employing an internal collection of gene expression profiles derived from HGSOC samples and cell lines [20,21], we found APAF1 as the experimentally validated and more anticorrelated miR-23a-3p target. Of note, miR-23a-3p over-expression together with APAF-1 downregulation characterized both platinum-resistant tumors and the ovarian carcinoma-stem-like cells (OVA-BS4 spheroids), previously reported by our group as highly resistant to platinum treatment. In addition, through a pilot in vitro study, we observed that by inhibiting miR-23a-3p expression, OSPC2 cells increase APAF1 levels, becoming more sensitive to carboplatin treatment, through an increase in apoptosis. On the contrary,
enhanced miR-23a-3p levels caused a reduction in APAF1 expression and decreased cell death in the OVCAR3 cells, thus inducing a platinum-resistant phenotype.

APAF1, the apoptotic protease-activating factor 1, is a key component of the intrinsic apoptotic pathway. Indeed, carboplatin causes DNA damage that induces apoptosis, and one of the potential mechanisms implicated in platinum resistance is the inhibition of apoptosis [44]. Previously reported evidence for the role of miRNAs in regulating APAF1 expression in the context of ovarian cancer exists. In particular, Yeung et al. showed that exosomal transfer of stroma-derived miR-21 to OC cells confers chemoresistance and an aggressive phenotype through binding to the APAF1 mRNA [44]. Additionally, Eoh et al. reported that an miR-630 inhibitor attenuated chemo-resistant OC proliferation and invasion, likely by targeting APAF1, re-sensitizing cells to chemotherapy [45]. The involvement of the miR-23a-3p/APAF1 axis has been reported in several solid cancers, including colorectal, pancreatic and laryngeal carcinomas and glioma [37,46]. However, to our knowledge, this is the first study demonstrating the implication of the miR-23a-3p/APAF1 axis in carboplatin resistance of HGSOC cells.

5. Conclusions

Our results indicate that miR-23a-3p could be considered a candidate biomarker to direct platinum therapy in HGSOC patients in the first line setting and in the subsequent lines of therapy. Additional studies in independent multicentric cohorts are needed to confirm the prognostic value of miR-23a-3p. Furthermore, strategies based on the upregulation of APAF1 might be explored as a novel therapeutic target and a tool to resensitize HGSOC cells to carboplatin treatment.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/cancers13133358/s1, Methods S1: Brescia and TCGA cohorts, Methods S2: Tissue collection and RNA extraction, Methods S3: miRNA and gene expression profiles, Methods S4: miRNA validation by reverse transcription-quantitative PCR (RT-qPCR), Methods S5: Selection of optimal reference miRNA for RT-qPCR data normalization, Methods S6: Characteristics of OVA-BS4 parental and OVA-BS4 spheroid cell lines, Methods S7: miRNA and gene expression profiles of OVA-BS4 parental and OVA-BS4 spheroid cell lines, Table S1: Characteristics of candidate miRNAs selected for RT-qPCR validation, Table S2: Brescia cohort—microarray Equivalence Test, Table S3: Brescia cohort-RT-qPCR. Equivalence Test, Methods S8: Cell lines and culture conditions, Methods S9: Cell transfection, Methods S10: Drug treatment, Methods S11: Apoptotic cell death detection, Methods S12: Apoptosis Analysis, Methods S13: RNA isolation from cell lines and RTqPCR, Methods S14: Western Blot, Results Table S1: Hypoxia-related miRNAs selected for expression analysis, Table S2: Overall survival analysis, Table S3: Complete results of Multivariate Survival Analysis, Table S4: Multivariate Progression-Free Survival Analysis (Coxph), Table S5: Multivariate Survival Analysis (Coxph) of the subgroup of 22 patients treated with bevacizumab, Table S6: Apoptosis cell death after carboplatin treatment in OSPC2 and OVCAR3 cell lines, Figure S1: miR-23a-3p expression in HGSOC cell lines by RTqPCR, Figure S2: miR-23a-3p expression modulation after transfection with inhibitor or mimic in HGSOC cell lines, Figure S3 upper panel. Immunoblots showing effect of miR-23a-3p modulation on APAF-1 expression before and after carboplatin treatment in HGSOC cell lines, Figure S3 bottom panel. Barplots representing apoptosis in HGSOC cell lines after transfection with miR-23a-3p inhibitor or mimic, followed by carboplatin treatment.

Author Contributions: P.T., E.S. (Elisa Salvato), C.R. (Chiara Romualdi) and E.B.: conceptualization, methodology, writing original draft; D.M.D.: conceptualization; C.R. (Chiara Romani), V.R., F.C., F.F., S.M., L.Z. and A.R.: investigation, visualization, formal analysis; G.T., M.D., F.O., E.S. (Enrico Sartori) and M.S.: writing—reviewing and editing. All authors have read and agreed to the published version of the manuscript.

Funding: We acknowledge (1) CARIPLO Foundation (Grant Number 2013-0815 to S. Marchini, E. Sartori and C. Romualdi), (2) EULO Foundation grant to F.Odicino, (3) Donazione Pizzini Maria Luisa and Donazione Astori Susanna to F. Odicino, (4) The Italian Association for Cancer Research (AIRC IG 21837 to C.R.). P. Todeschini and C. Romani are recipients of scholarships from Fondazione Umberto Veronesi.
Institutional Review Board Statement: The study on the Brescia cohort was performed following the Declaration of Helsinki set of principles and approved by the Research Review Board—the Ethics Committee—of the ASST-Spedali Civili, Brescia, Italy (study reference number: NP1676).

Informed Consent Statement: Written informed consent was obtained from all patients enrolled.

Data Availability Statement: The data presented in this study are openly available in EMBL-EBI ArrayExpress repository, reference number E-MTAB-7084 (miRNA microarray, Brescia cohort), E-MTAB-7083 (mRNA microarray, Brescia cohort), ‘pending number’ (miRNA microarray, HGSOC-stem like cells) and E-MTAB-4799 (mRNA microarray, HGSOC-stem like cells). Publicly available datasets were analyzed in this study. These data can be found in NIH GDC Data Portal, reference project TCGA-OV (miRNA RNA-seq, TCGA cohort).

Acknowledgments: We wish to thank Adele Bellandi for her excellent support to the project. We also highly appreciated the essential contribution of all the nurses working in the OR and in the Division of Obstetrics and Gynecology, ASST Spedali Civili di Brescia in the collection of tissue samples.

Conflicts of Interest: The authors have declared that no competing interest exists.

References

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer Statistics, 2020. CA Cancer J. Clin. 2020, 70, 7–30. [CrossRef] [PubMed]
2. Bowtell, D.D.; Böhm, S.; Ahmed, A.A.; Aspuria, P.J.; Bast, R.C.; Beral, V.; Berek, J.S.; Birrer, M.J.; Blagden, S.; Bookman, M.A.; et al. Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer 2015, 15, 668–679. [CrossRef]
3. Eales, K.L.; Hollinshead, K.E.; Tennant, D.A. Hypoxia and metabolic adaptation of cancer cells. Oncogenesis 2016, 5, e190. [CrossRef] [PubMed]
4. Gómez-Raposo, C.; Mendiola, M.; Barriuso, J.; Casado, E.; Hardisson, D.; Redondo, A. Angiogenesis and ovarian cancer. Clin. Transl. Oncol. 2009, 11, 564–571. [CrossRef] [PubMed]
5. Paolich, E.; Gemignani, F.; Krstic-Demonacos, M.; Dedhar, S.; Mutti, L.; Landi, S. Targeting hypoxic response for cancer therapy. Oncotarget 2016, 7, 13464–13478. [CrossRef] [PubMed]
6. Choi, H.J.; Armaiz Pena, G.N.; Pradeep, S.; Cho, M.S.; Coleman, R.L.; Sood, A.K. Anti-vascular therapies in ovarian cancer: Moving beyond anti-VEGF approaches. Cancer Metastasis Rev. 2015, 34, 19–40. [CrossRef]
7. Sennino, B.; McDonald, D.M. Controlling escape from angiogenesis inhibitors. Nat. Rev. Cancer 2012, 12, 699–709. [CrossRef]
8. Aghajanian, C.; Blank, S.V.; Goff, B.A.; Judson, P.L.; Teneriello, M.G.; Husain, A.; Sovak, M.A.; Yi, J.; Nycum, L.R. OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J. Clin. Oncol. 2012, 30, 2039–2045. [CrossRef]
9. Kulshreshtha, R.; Ferracini, M.; Wojcik, S.E.; Garzon, R.; Alers, H.; Agusto-Perez, F.J.; Davuluri, R.; Liu, C.-G.; Croce, C.M.; Negrini, M.; et al. A MicroRNA Signature of Hypoxia. Mol. Cell. Biol. 2007, 27, 1859–1867. [CrossRef]
10. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474, 609–615. [CrossRef]
11. Giannakakis, A.; Sandaltzopoulos, R.; Greshock, J.; Liang, S.; Huang, J.; Hasegawa, K.; Li, C.; O’Brien-Jenkins, A.; Katsaros, D.; Weber, B.L.; et al. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol. Ther. 2008, 7, 255–264. [CrossRef] [PubMed]
12. Polytarchou, C.; Iliopoulos, D.; Hatziapostolou, M.; Kottakis, F.; Maroulakou, I.; Struhl, K.; Tsichlis, P.N. Akt2 regulates Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation. Cancer Res. 2011, 71, 4720–4731. [CrossRef]
13. Xu, Q.; Liu, L.-Z.; Qian, X.; Chen, Q.; Jiang, Y.; Li, D.; Lai, L.; Jiang, B.-H. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res. 2011, 40, 761–774. [CrossRef] [PubMed]
14. He, J.; Jing, Y.; Li, W.; Qian, X.; Xu, Q.; Li, F.-S.; Liu, L.-Z.; Jiang, B.-H.; Jiang, Y. Roles and Mechanism of miR-199a and miR-125b in Tumor Angiogenesis. PLoS ONE 2013, 8, e56647. [CrossRef]
15. Yeh, Y.-M.; Chuang, C.-M.; Chao, K.-C.; Wang, L.-H. MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1α. Int. J. Cancer 2013, 133, 867–878. [CrossRef] [PubMed]
16. Joshi, H.P.; Subramanian, I.V.; Schnettler, E.K.; Ghosh, G.; Rupaimoole, R.; Evans, C.; Saluja, M.; Jing, Y.; Cristina, I.; Roy, S.; et al. Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis. Proc. Natl. Acad. Sci. USA 2014, 111, 5331–5336. [CrossRef]
17. Kinose, Y.; Sawada, K.; Nakamura, K.; Sawada, I.; Toda, A.; Nakatsuka, E.; Hashimoto, K.; Mabuchi, S.; Takahashi, K.; Kurachi, H.; et al. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma. Oncotarget 2015, 6, 11342–11356. [CrossRef]
18. Rupaimoole, R.; Ivan, C.; Yang, D.; Gharpure, K.M.; Wu, S.Y.; Pecot, C.V.; Previs, R.A.; Nagaraja, A.; Armaiz-Pena, G.N.; McGuire, M.; et al. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. *Oncogene* 2016, 35, 4312–4320. [CrossRef] [PubMed]

19. Pfister, J.; Ledermann, J.A. Management of Platinum-Sensitive Recurrent Ovarian Cancer. *Semin. Oncol.* 2006, 33, 12–16. [CrossRef]

20. Todeschini, P.; Salvato, E.; Paracchini, L.; Ferracin, M.; Petrillo, M.; Zanotti, L.; Tognon, G.; Gambino, A.; Calura, E.; Caratti, G.; et al. Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts. *Cancer Lett.* 2017, 388, 320–327. [CrossRef]

21. Benvenuto, G.; Todeschini, P.; Paracchini, L.; Calura, E.; Fruscio, R.; Romani, C.; Beltrame, L.; Martini, P.; Ravaggi, A.; Ceppi, L.; et al. Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer. *Int. J. Cancer* 2020, 147, 565–574. [CrossRef]

22. Bignotti, E.; Calza, S.; Tassi, R.A.; Zanotti, L.; Bandiera, E.; Sartori, E.; Odicino, F.E.; Ravaggi, A.; Todeschini, P.; Romani, C. Identification of stably expressed reference small non-coding RNA s for micro RNA quantification in high-grade serous ovarian carcinoma tissues. *J. Cell. Mol. Med.* 2016, 20, 2341–2348. [CrossRef] [PubMed]

23. Schwarzenbach, H.; Silva, A.M.; Calin, G.; Pantel, K. Data Normalization Strategies for MicroRNA Quantification. *Clin. Chem.* 2015, 61, 1333–1342. [CrossRef] [PubMed]

24. Love, M.I.; Huber, W.; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* 2014, 15, 550. [CrossRef] [PubMed]

25. Ritchie, M.; Phipson, B.; Wu, D.; Hu, Y.; Law, C.W.; Shi, W.; Smyth, G.K. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* 2015, 43, e47. [CrossRef]

26. Zanotti, L.; Romani, C.; Tassone, L.; Todeschini, P.; Tassi, R.A.; Bandiera, E.; Sartori, E.; Odicino, F.E.; Ravaggi, A.; Todeschini, P.; Romani, C. Identification of stably expressed reference small non-coding RNA s for micro RNA quantification in high-grade serous ovarian carcinoma tissues. *J. Cell. Mol. Med.* 2016, 20, 2341–2348. [CrossRef] [PubMed]

27. Hauck, W.W.; Anderson, S. A new statistical procedure for testing equivalence in two-group comparative bioavailability trials. *J. Pharmacokinet. Biopharm.* 1984, 12, 83–91. [CrossRef]

28. Wellek, S. *Testing Statistical Hypotheses of Equivalence and Noninferiority*; CRC Press: Boca Raton, FL, USA, 2010.

29. Paraskevopoulou, M.D.; Georgakilas, G.; Kostoulas, N.; Vlachos, I.; Vergoulis, T.; Reczko, M.; Filippidis, C.; Dalamagas, T.; Hatzigeorgiou, A.G. DIANA-microT web server v5.0: Service integration into miRNA functional analysis workflows. *Nucleic Acids Res.* 2013, 41, W169–W173. [CrossRef]

30. Agarwal, V.; Bell, G.W.; Nam, J.-W.; Bartel, D.P. Predicting effective microRNA target sites in mammalian mRNAs. *eLife* 2015, 4, e05005. [CrossRef]

31. Backes, C.; Keller, A.; Kuentzer, J.; Kneissl, B.; Comtesse, N.; Elnakady, Y.; Meessen, H.-P. GeneTrail–advanced gene set enrichment analysis. *Nucleic Acids Res.* 2007, 35, W186–W192. [CrossRef] [PubMed]

32. Sales, G.; Calura, E.; Cavaliere, D.; Romualdi, C. Graphite—A Bioconductor package to convert pathway topology to gene network. *BMC Bioinform.* 2012, 13, 20. [CrossRef]

33. Karagkouni, D.; Paraskevopoulou, M.D.; Chatzopoulou, S.; Vlachos, I.; Tsatsoglou, S.; Kanellos, I.; Papadimitriou, D.; Kavakiotis, I.; Maniou, S.; Skoufos, G.; et al. DIANA-TarBase v8: A decade-long collection of experimentally supported miRNA–gene interactions. *Nucleic Acids Res.* 2018, 46, D239–D245. [CrossRef]

34. Burger, R.A.; Brady, M.F.; Bookman, M.A.; Fleming, G.F.; Monk, B.J.; Huang, H.; Mannel, R.S.; Homesley, H.D.; Fowler, J.; Greer, B.E.; et al. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. *N. Engl. J. Med.* 2011, 365, 2473–2483. [CrossRef]

35. Tewari, K.S.; Burger, R.A.; Enserro, D.; Norquist, B.M.; Swisher, E.M.; Brady, M.F.; Bookman, M.A.; Fleming, G.; Huang, H.; Homesley, H.D.; et al. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. *J. Clin. Oncol.* 2019, 37, 2317–2328. [CrossRef]

36. O’Brien, J.; Hayden, H.; Zayed, Y.; Peng, C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. *Front. Endocrinol.* 2018, 9, 402. [CrossRef] [PubMed]

37. Yong, F.L.; Wang, C.W.; Roslani, A.C.; Law, C.W. The Involvement of miR-23a/APAF1 Regulation Axis in Colorectal Cancer. *Int. J. Mol. Sci.* 2014, 15, 11713–11729. [CrossRef]

38. Su, L.; Liu, M. Correlation analysis on the expression levels of microRNA-23a and microRNA-23b and the incidence and prognosis of ovarian cancer. *Oncol. Lett.* 2018, 16, 262–266. [CrossRef]

39. Vaksman, O.; Stavnes H.T.; Kaern, J.; Trope, C.G.; Davidson, B.; Reich, R. miRNA profiling along tumour progression in ovarian carcinoma. *J. Cell. Mol. Med.* 2011, 15, 1593–1602. [CrossRef]

40. Jin, A.-H.; Wei, Z.-L. Molecular mechanism of increased sensitivity of cisplatin to ovarian cancer by inhibition of microRNA-23a expression. *Int. J. Clin. Exp. Med.* 2015, 8, 13329–13334. [PubMed]

41. Yang, Z.; Wang, X.-L.; Bai, R.; Liu, W.-Y.; Li, X.; Liu, M.; Tang, H. miR-23a promotes IKKα expression but suppresses ST7L expression to contribute to the malignancy of epithelial ovarian cancer cells. *Br. J. Cancer* 2016, 115, 731–740. [CrossRef] [PubMed]

42. Prahm, K.P.; Høgdall, C.; Karlsten, M.A.; Christensen, I.J.; Novotny, G.W.; Høgdall, E. Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer. *PLoS ONE* 2018, 13, e0207319. [CrossRef] [PubMed]
43. Zhuang, R.-J.; Bai, X.-X.; Liu, W. MicroRNA-23a depletion promotes apoptosis of ovarian cancer stem cell and inhibits cell migration by targeting DLG2. Cancer Biol. Ther. 2019, 20, 897–911. [CrossRef] [PubMed]

44. Yeung, C.L.A.; Co, N.-N.; Tsuruga, T.; Yeung, T.-L.; Kwan, S.-Y.; Leung, C.S.; Li, Y.; Lu, E.S.; Kwan, K.; Wong, K.-K.; et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat. Commun. 2016, 7, 11150. [CrossRef] [PubMed]

45. Eoh, K.J.; Lee, S.H.; Kim, H.J.; Lee, J.-Y.; Kim, S.; Kim, S.W.; Kim, Y.T.; Nam, E.J. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis. Biochem. Biophys. Res. Commun. 2018, 497, 513–520. [CrossRef] [PubMed]

46. Wang, N.; Tan, H.-Y.; Feng, Y.-G.; Zhang, C.; Chen, F.; Feng, Y. microRNA-23a in Human Cancer: Its Roles, Mechanisms and Therapeutic Relevance. Cancers 2018, 11, 7. [CrossRef]